U.S. Food and Drug Administration Approval: Neratinib for the Extended Adjuvant Treatment of Early Stage HER2-Positive Breast Cancer.

This article summarizes FDA decision-making and data supporting the neratinib approval.
PMID: 29523624 [PubMed - as supplied by publisher]

Source: Clinical Cancer Research - March 9, 2018 Category: Cancer & Oncology Authors: Singh H, Walker AJ, Amiri-Kordestani L, Cheng J, Tang S, Balcazar P, Barnett-Ringgold K, Palmby TR, Cao X, Zheng N, Liu Q, Yu J, Pierce WF, Daniels SR, Sridhara R, Ibrahim A, Kluetz PG, Blumenthal GM, Beaver JA, Pazdur R Tags: Clin Cancer Res Source Type: research